AbbVie (ABBV)
(Delayed Data from NYSE)
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $193.90 -0.39 (-0.20%) 7:16 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $193.90 -0.39 (-0.20%) 7:16 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Zacks News
The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, NextEra Energy, The Boeing and Canadian Natural Resources
by Zacks Equity Research
JPMorgan Chase, AbbVie, NextEra Energy, The Boeing and Canadian Natural Resources are part of the Zacks top Analyst Blog.
Top Research Reports for JPMorgan Chase, AbbVie & NextEra Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and NextEra Energy, Inc. (NEE).
Why AbbVie (ABBV) Could Beat Earnings Estimates Again
by Zacks Equity Research
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AbbVie (ABBV) Stock Moves 0.06%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $161.38, moving +0.06% from the previous trading session.
AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica
by Zacks Equity Research
AbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two blood cancer treatments is based on confirmatory studies data that do not support full approval.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
Johnson & Johnson (JNJ) Soars 4.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Johnson & Johnson (JNJ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $160.42 in the latest trading session, marking a +0.66% move from the prior day.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $157.54, marking a -0.3% move from the previous day.
The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly
by Zacks Equity Research
Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.
AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs
by Zacks Equity Research
AbbVie???s (ABBV) two studies evaluating Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus meet their primary endpoints.
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
by Kinjel Shah
Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951
AbbVie (ABBV) Gets FDA Rejection for Parkinson's Candidate
by Zacks Equity Research
In the CRL, the FDA asks AbbVie (ABBV) for some extra information about the pump device used to administer the Parkinson's disease medicine, ABBV-951.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's What is Driving Amgen (AMGN) Stock's Outperformance
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $156.12, marking a +1.23% move from the previous day.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
The Zacks Analyst Blog Highlights AbbVie, NextEra Energy, ConocoPhillips, Canadian Pacific Railway and Intercontinental Exchange
by Zacks Equity Research
AbbVie, NextEra Energy, ConocoPhillips, Canadian Pacific Railway and Intercontinental Exchange are part of the Zacks top Analyst Blog.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $151.95, marking a +1.5% move from the previous day.
Top Research Reports for AbbVie, NextEra Energy & ConocoPhillips
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NextEra Energy, Inc. (NEE) and ConocoPhillips (COP).
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks Investment Ideas feature highlights: Coca-Cola Company, AbbVie and Exxon Mobil
by Zacks Equity Research
Coca-Cola Company, AbbVie and Exxon Mobil have been highlighted in this Investment Ideas article.